Nonetheless, both IBD and mouse experimental colitides are marked by a defective activity of TGF-β1, which is due to the enhanced expression of Smad7, an inhibitor of TGF-β1 signaling [12,13,14,15,16]. The gene discussed is SMAD7; the disease is inflammatory bowel disease.